David C. Sachs - Sep 9, 2021 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Chief Financial Officer
Signature
/s/ Steven Yang, as Attorney-in-Fact
Stock symbol
IBRX
Transactions as of
Sep 9, 2021
Transactions value $
$0
Form type
4
Date filed
9/13/2021, 08:34 PM
Next filing
Dec 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +7.6K +40.29% $0.00 26.5K Sep 9, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -7.6K -4.49% $0.00 162K Sep 9, 2021 Common Stock 7.6K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 17,242 of the restricted stock units ("RSUs") will vest on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) will vest on September 9, 2021; five percent (5%) of the Units (rounded down to the nearest whole share) will vest on the earlier of (A) December 31, 2022 and (B) the 60th day following approval by the Food and Drug Administration (FDA) of a biologics license application (BLA) or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the Units (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining Units will vest on December 31, 2026.

Remarks:

Exhibit 24 - Power of Attorney